Miller Fisher Syndrome (MFS) is a rare variant of Guillain-Barre Syndrome (GBS) that is generally treatable but leaves some patients struggling to cope with permanent complications. There is a recognized link between MFS and certain vaccinations, and individuals diagnosed with MFS following a flu or tetanus shot may be entitled to financial compensation.
Although MFS is among the rarer variants of GBS, its potential effects are also among the most serious for those diagnosed with the disorder. While most symptoms of Miller Fisher Syndrome subside within a few months, many individuals diagnosed with MFS experience permanent complications. Regardless, a prompt diagnosis and effective treatment plan are critical, and individuals diagnosed with MFS must ensure they have the financial resources necessary to cover the costs of their treatment and recovery.
As a variant of GBS, MFS is a condition for which compensation may be available under the National Vaccine Injury Compensation Program (VICP). The VICP is a federal government program that allows individuals diagnosed with vaccine-related illnesses to collect compensation for their medical bills, pain and other losses without the need to pursue traditional lawsuits against hospitals and pharmaceutical companies. But, while the VICP has paid billions of dollars to claimants, pursuing a successful claim and maximizing the compensation awarded requires strategic representation from an experienced vaccine attorney.
About Vaccine-Related MFS
MFS is a nerve disease that is typically characterized by three discrete symptoms:
- Weakening of the eye muscles, which can result in double or blurred vision, drooping eyelids, and potential paralysis of the eye muscles
- Loss of muscle coordination, resulting in poor balance and difficulty walking
- Loss of deep tendon reflexes, which can lead to jerking of the ankles and knees, as well as other side effects
Most often, patients seek treatment for MFS following a rapid decrease in eyesight, walking coordination or both. Individuals with MFS may also notice dilated pupils or weak face muscles. In any case, seeking a prompt medical diagnosis is critical, as early treatment can help reduce the risks of long-term effects and possible respiratory failure.
The primary treatment options for MFS are the same as the treatment options for GBS, which are plasmapheresis (plasma exchange) and immunoglobulin therapy. In certain circumstances, individuals diagnosed with MFS may also need to be monitored for additional symptoms that may be indicative of GBS.
With appropriate treatment, the symptoms of MFS can begin to subside in as little as two to four weeks, and data from the National Institutes of Health (NIH) indicate that most patients make a near-complete recovery within six months. However, it is possible for individuals diagnosed with MFS to experience permanent effects, and in a small percentage of cases relapses can occur.
Inquire about Seeking Compensation for MFS Caused by a Flu or Tetanus Vaccination
If you have been diagnosed with MFS and would like more information about filing a claim under the VICP, contact GBS Vaccine Lawyer to schedule a free, no-obligation consultation. We have a medical doctor on staff, and our experienced vaccine attorney represents clients in VICP claims nationwide. Protect your claim for compensation – call (202) 775-9200 or request an appointment online now.